These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 16859390)

  • 1. Toll-like receptor modulation in cardiovascular disease: a target for intervention?
    Földes G; von Haehling S; Anker SD
    Expert Opin Investig Drugs; 2006 Aug; 15(8):857-71. PubMed ID: 16859390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Toll-like receptors in infection and immunity: clinical implications.
    Cristofaro P; Opal SM
    Drugs; 2006; 66(1):15-29. PubMed ID: 16398566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of Toll-Like Receptors 2, 3, 4, and 8 Is Correlated to the Vascular Atherosclerotic Process in the Hyperlipidemic Rabbit Model: The Effect of Statin Treatment.
    Kapelouzou A; Giaglis S; Peroulis M; Katsimpoulas M; Moustardas P; Aravanis CV; Kostakis A; Karayannakos PE; Cokkinos DV
    J Vasc Res; 2017; 54(3):156-169. PubMed ID: 28478461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway.
    Yin QY; Zhao B; Qiu YY; Fei YX; Hu YH; Li YM
    J Cardiovasc Pharmacol; 2019 Nov; 74(5):379-388. PubMed ID: 31730559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD.
    Ji J; von Schéele I; Billing B; Dahlén B; Lantz AS; Larsson K; Palmberg L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1035-43. PubMed ID: 27274225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease?
    Katsargyris A; Klonaris C; Bastounis E; Theocharis S
    Expert Opin Ther Targets; 2008 Nov; 12(11):1329-46. PubMed ID: 18851691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine is an anti-inflammatory TLR-2, -4 and -5 response mediator in human monocytes.
    Wang H; Graves MW; Zhou H; Gu Z; Lamont RJ; Scott DA
    Inflamm Res; 2016 Jan; 65(1):61-9. PubMed ID: 26613980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the toll-system in cardiovascular sciences.
    Földes G; von Haehling S; Jankowska EA; Anker SD
    Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):57-67. PubMed ID: 19075967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immunity and toll-like receptor antagonists: a potential role in the treatment of cardiovascular diseases.
    Lin E; Freedman JE; Beaulieu LM
    Cardiovasc Ther; 2009; 27(2):117-23. PubMed ID: 19426249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Saturated fatty acids do not directly stimulate Toll-like receptor signaling.
    Erridge C; Samani NJ
    Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1944-9. PubMed ID: 19661481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of statins on toll-like receptors: a new insight to pleiotropic effects.
    Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A
    Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of inflammatory cells and toll-like receptors in atherosclerosis.
    Seneviratne AN; Monaco C
    Curr Vasc Pharmacol; 2015; 13(2):146-60. PubMed ID: 24188491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toll-Like Receptors: Regulators of the Immune Response in the Human Gut.
    Hug H; Mohajeri MH; La Fata G
    Nutrients; 2018 Feb; 10(2):. PubMed ID: 29438282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma.
    Erridge C; Burdess A; Jackson AJ; Murray C; Riggio M; Lappin D; Milligan S; Spickett CM; Webb DJ
    Eur J Clin Invest; 2008 Oct; 38(10):713-20. PubMed ID: 18837796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Polymorphisms of the Toll-like receptor 4 gene and their potential role in infectious diseases and chronic inflammatory disorders].
    Reismann P; Rácz K; Tulassay Z
    Orv Hetil; 2008 Sep; 149(38):1791-9. PubMed ID: 18805765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic role of toll-like receptor modification in cardiovascular dysfunction.
    Navi A; Patel H; Shaw S; Baker D; Tsui J
    Vascul Pharmacol; 2013 Mar; 58(3):231-9. PubMed ID: 23070056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR signalling and association of TLR polymorphism with cardiovascular diseases.
    Sharma S; Garg I; Ashraf MZ
    Vascul Pharmacol; 2016 Dec; 87():30-37. PubMed ID: 27826031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease.
    Jia SJ; Niu PP; Cong JZ; Zhang BK; Zhao M
    Int Immunopharmacol; 2014 Nov; 23(1):54-9. PubMed ID: 25158302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel function of TLR4 in mediating the immunomodulatory effect of Benzanthrone, an environmental pollutant.
    Tewari P; Mandal P; Roy R; Asthana S; Dwivedi PD; Das M; Tripathi A
    Toxicol Lett; 2017 Jul; 276():69-84. PubMed ID: 28495615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating atherosclerosis: the potential of Toll-like receptors as therapeutic targets.
    Cole JE; Mitra AT; Monaco C
    Expert Rev Cardiovasc Ther; 2010 Nov; 8(11):1619-35. PubMed ID: 21090937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.